EpiVax is a private drug discovery and development company specializing in the deimmunization of protein therapeutics and vaccine design/development. The company applies proprietary in silico epitope profiling with in vitro and in vivo assays to predict and modulate immune response. The EpiVax approach is biologically validated and the Company has been solving immunogenicity problems for major pharmaceutical, biotechnology, and agribusiness partners for the past 8 years. Collaborators most effectively incorporate EpiVax’s technology into their pre-clinical compound selection process or apply it to deimmunize a lead compound in clinical trials. Grant supported work on vaccines for Smallpox, Tularemia, TB, and H. Pylori underpin our technology development efforts. EpiVax has, and continues to seek, collaborations with major pharmaceutical and biotech companies.